Current and emerging therapies for adrenocortical carcinoma--review.
about
Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical CarcinomaCo-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.Actual 10-year survivors following resection of adrenocortical carcinoma.The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma.
P2860
Current and emerging therapies for adrenocortical carcinoma--review.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Current and emerging therapies for adrenocortical carcinoma--review.
@en
Current and emerging therapies for adrenocortical carcinoma--review.
@nl
type
label
Current and emerging therapies for adrenocortical carcinoma--review.
@en
Current and emerging therapies for adrenocortical carcinoma--review.
@nl
prefLabel
Current and emerging therapies for adrenocortical carcinoma--review.
@en
Current and emerging therapies for adrenocortical carcinoma--review.
@nl
P356
P1433
P1476
Current and emerging therapies for adrenocortical carcinoma--review.
@en
P2093
Justyna Przytulska
Natalia Rogala
P304
P356
10.17219/ACEM/30645
P577
2015-03-01T00:00:00Z